mira.patel
TL4 Administrator Co-founder · Documentation · Manchester, UK
Co-founder and documentation lead. My job is turning good threads into maintained pages. If a topic keeps being re-asked, that is a documentation failure and I would like to hear about it. Background in technical writing for analytical instrument vendors.
Joined 16 May 2024 · last posted 10h · groups: staff, moderators, wiki-editors, regional-apac, trust-level-4
223Posts here
7Topics
0Solutions
2.3kLikes received
1kLikes given
33Badges
125Days visited
6.7kPosts read
Recent activity
Full stream-
I joined for one answer and stayed for a year — what changed my mind Replied, post #114 · Start Here › Welcome · 27 Jul 2026 · 9 likes Nothing here requires expertise. The experienced members here got that way by posting questions, not by knowing the answer before they showed up. If you know something…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #61 · Clinical › Bloodwork · 25 Jul 2026 · 0 likes Post #60 is the version of this I will quote in future. One addition. Glycaemic markers integrate over different periods. A point glucose and a longer-term marker…
-
Here for the analytics and not much else Replied, post #87 · Lounge › Introductions · 24 Jul 2026 · 0 likes Welcome from staff. Nothing is required of you here — no posting quota, no introduction, no declaration of background. The only thing we ask is that a claim about a…
-
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #66 · Analytics › HPLC & UHPLC · 24 Jul 2026 · 7 likes This follows post #63 rather than contradicting it. Carryover from a previous injection shows up as a small peak at the same retention time in a blank. A method report…
-
Submitting a sample: the process end to end Replied, post #106 · Sourcing › Independent verification · 24 Jul 2026 · 2 likes Post #103 is the version of this I will quote in future. One addition. A record with four results over sixteen months is a thin record rather than a bad one, and the…
-
Follow-up: Reading an interaction checker output critically Replied, post #58 · Practice › Interactions · 21 Jul 2026 · 2 likes I had read the opposite somewhere and cannot now find where, which tells me something.
-
Trust level 3 requirements: a clarification — does this still hold? Replied, post #86 · Meta › Announcements · 20 Jul 2026 · 19 likes Clarification on the announcement, because two people have now read it the same wrong way. That is a writing failure rather than a reading one, and the original has…
-
Request: a per-category review queue Replied, post #115 · Meta › Feature requests · 19 Jul 2026 · 7 likes Both of these are in the same family and staff would rather do one thing well than two things partly. If the range link exists, the citation relationship gets much…
-
Restarting after a long gap: what the labelling implies Replied, post #29 · Practice › Dosing & titration · 16 Jul 2026 · 23 likes A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #35 · Access › Insurance & coverage · 16 Jul 2026 · 15 likes Answering the question post #31 raises rather than the one it answers. Formulary changes happen on a published schedule, so a denial now may be answering criteria that…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #30 · Access › Insurance & coverage · 15 Jul 2026 · 0 likes Keep every document with dates in one place. An appeal months later is assembled from whatever you kept.
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #3 · Clinical › Bloodwork · 15 Jul 2026 · 0 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
Maintains 32 documents
- Semaglutide — referenceReview due 17 Apr 2027
- Retatrutide — referenceReview due 4 Dec 2026
- Liraglutide — referenceReview due 8 Mar 2027
- Orforglipron — referenceReview due 11 Jun 2027
- Oral semaglutide — referenceReview due 24 Jan 2027
- TB-500 — referenceReview due 3 Oct 2026
- Growth-hormone-releasing peptides (GHRP class) — referenceReview due 14 Mar 2027
- Tesamorelin — referenceReview due 21 Aug 2026
- Access notes: FranceReview due 10 May 2027
- Access notes: NetherlandsReview due 9 Aug 2026